Myeloma EHA 2025 preview
The European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, will take place from 12 – 15 June in Milan, Italy. The meeting will bring together experts from across the globe…
The European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, will take place from 12 – 15 June in Milan, Italy. The meeting will bring together experts from across the globe…
On the 23 May 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of two belantamab mafodotin combinations for the treatment of patients with relapsed and/or refractory myeloma. The first combination is…
Prothena, the pharmaceutical company that produce the AL amyloidosis drug birtamimab, have announced that the Phase III AFFIRM-AL clinical trial failed to meet its primary endpoint – i.e., the main result being measured in the…
Myeloma Patients Europe (MPE) will host a webinar on “Living well with AL amyloidosis” on Thursday, 5 June 2025 from 17:00 – 18:00 CEST. Aimed at AL amyloidosis patients and patient advocates, the webinar will…
It is with great sadness that we share the news of the passing of our friend, colleague, and fellow patient advocate, Reidar Nordby. With his passing, Myeloma Patients Europe (MPE) has lost not only a…
On 23th April 2025, the European Commission has granted conditional marketing approval of linvoseltamab to treat adults with relapsed and refractory myeloma. Conditional approval means that linvoseltamab will be reassessed for safety and efficacy when…
The Horizon Europe funded project ASCERTAIN invites you to the webinar “How do different countries make decisions on reimbursing new medicines?” The webinar will take place on Wednesday 2nd April 2025, from 16:00 to 17:30…
On 27th February 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma. The CHMP is the European Medicines Agency’s committee…